Clinical Trial Update: Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 clinical trial is evaluating NUDT21-targeting siRNA therapies for patients with refractory retinoblastoma. The study is sponsored by the Eye & …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinoblastoma

Drugs mentioned

• NUDT21 siRNA (NUDT21 siRNA)

Snippet

Sponsor: Eye & ENT Hospital of Fudan University | Conditions: Retinoblastoma, Refractory | EARLY_Phase 1 | Status: RECRUITING